Page last updated: 2024-09-05

erlotinib hydrochloride and ecteinascidin 743

erlotinib hydrochloride has been researched along with ecteinascidin 743 in 1 studies

Compound Research Comparison

Studies (erlotinib hydrochloride)	Trials (erlotinib hydrochloride)	Recent Studies (post-2010) (erlotinib hydrochloride)	Studies (ecteinascidin 743)	Trials (ecteinascidin 743)	Recent Studies (post-2010) (ecteinascidin 743)
4,353	786	3,033	660	102	404

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Sabbatini, P	1

Other Studies

1 other study(ies) available for erlotinib hydrochloride and ecteinascidin 743

Article	Year
New agents and new formulations for the treatment of ovarian cancer. Clinical advances in hematology & oncology : H&O, 2005, Volume: 3, Issue:11 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-125 Antigen; Dioxoles; Erlotinib Hydrochloride; Female; Humans; Isoquinolines; Ovarian Neoplasms; Predictive Value of Tests; Quinazolines; Recurrence; Remission Induction; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Vascular Endothelial Growth Factor A	2005

Article

Year

New agents and new formulations for the treatment of ovarian cancer.

Clinical advances in hematology & oncology : H&O, 2005, Volume: 3, Issue:11

Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-125 Antigen; Dioxoles; Erlotinib Hydrochloride; Female; Humans; Isoquinolines; Ovarian Neoplasms; Predictive Value of Tests; Quinazolines; Recurrence; Remission Induction; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Vascular Endothelial Growth Factor A

2005